- Novartis CEO says latest China deals are just following the scienceNovartis isn't making deals in China just for the sake of buying there. That's the word from CEO Vas Narasimhan, who told reporters on a second-quarter earnings call that the Swiss pharma is “agn…Endpoints · 3d ago↗ source
- Gilead and Merck provide HIV data; Dimension Capital announces $800M fundGilead and Merck’s HIV data: The duo will present more detailed results of the Phase 3 trials of their once-weekly oral HIV treatment regimen at AIDS 2026, one of the largest ...Endpoints · 3d ago↗ source
- Agios’ second shot at sickle cell disease falls shortAgios said it is dropping a next-generation sickle cell disease drug after lackluster results from a mid-stage trial. The drug, known as tebapivat, represented Agios’ second shot at the disease,…